Cirtuvivint
A Phase I Study Evaluating the Safety of Cirtuvivint as Monotherapy and in Combination With ASTX727 and ASTX727 + Venetoclax in Patients With Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 54 patients (estimated)
- Sponsors
- National Cancer Institute (NCI)
- Tags
- CLK Inhibitor
- Trial Type
- Treatment
- Last Update
- 1 day ago
- SparkCures ID
- 2036
- NCT Identifier
- NCT06484062
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.